Donor KIR Genes 2DL5A, 2DS1 and 3DS1 Are Associated with a Reduced Rate of Leukemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for Acute Myeloid Leukemia but Not Other Hematologic Malignancies

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 9, 2010, Pages 1257-1264

  Stringaris, Kate ^a   Adams, Sharon ^b   Uribe, Marcela ^b   Eniafe, Rhoda ^a   Wu, Colin O ^a   Savani, Bipin N ^c   Barrett, A John ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Activatory KIR; Acute myelogenous leukemia; NK cells; Relapse; Stem cell transplantation

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL5A; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHILD; CHRONIC GRANULOCYTIC LEUKEMIA; CONTROLLED STUDY; FEMALE; GENOTYPE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; RISK FACTOR; SCHOOL CHILD; SIBLING; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 77955512395     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.03.004     Document Type: Article

References (22)

1. Kumar S., Chen M.G., Gastineau D.A., et al. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 2001, 28:951-956.
2. Kumar S., Chen M.G., Gastineau D.A., et al. Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. Leukemia 2003, 17:1865-1870.
3. Kim D.H., Kim J.G., Sohn S.K., et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 2004, 125:217-224.
4. Savani B.N., Mielke S., Rezvani K., et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:1216-1223.
5. Ishaqi M.K., Afzal S., Dupuis A., Doyle J., Gassas A. Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia. Bone Marrow Transplant 2008, 41:245-252.
6. Dunbar E.M., Buzzeo M.P., Levine J.B., Schold J.D., Meier-Kriesche H.U., Reddy V. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Haematologica 2008, 93:1852-1858.
7. Savani B.N., Mielke S., Adams S., et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007, 21:2145-2152.
8. Ljunggren H.G., Karre K. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today 1990, 11:237-244.
9. Cooley S., Trachtenberg E., Bergemann T.L., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009, 15(113):726-732.
10. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
11. Hsu K.C., Keever-Taylor C.A., Wilton A., et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005, 105:4878-4884.
12. Leung W., Iyengar R., Turner V., et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004, 172:644-650.
13. Kroger N., Binder T., Zabelina T., et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006, 82:1024-1030.
14. Witt C.S., Dewing C., Sayer D.C., Uhrberg M., Parham P., Christiansen F.T. Population frequencies and putative haplotypes of the killer cell immunoglobulin-like receptor sequences and evidence for recombination. Transplantation 1999, 68:1784-1789.
15. Cook M.A., Milligan D.W., Fegan C.D., et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004, 103:1521-1526.
16. Middleton D, Menchaca L, Rood H, Komerofsky R. New allele frequency database: Tissue Antigens. 2003;61:403-407. http://www.allelefrequencies.net.
17. Ringden O., Barrett A.J., Zhang M.J., et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol 2003, 121:874-885.
18. Savani B.N., Rezvani K., Mielke S., et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006, 107:1688-1695.
19. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999, 94:333-339.
20. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
21. Berg M., Lundqvist A., McCoy P., et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009, 11:341-355.
22. Passweg J.R., Tichelli A., Meyer-Monard S., et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004, 18:1835-1838.